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Abstract An analogue of human melanin-concentrating 
hormone (MCH) suitable for radioiodination was designed in 
which Tyr t3 was replaced by Phe and VaP 9 by Tyr. The resulting 
monoiodinated [125I][Phei3,Tyr19]-MCH radioligand was biolog- 
ically active and led to the discovery of high-affinity binding sites 
on mouse B16-F1, G4F and G4F-7 melanoma cells. Saturation 
binding analysis with G4F-7 cells revealed 1090 MCH receptors 
per cell and a KD of 1.18 x 10 -1° mol/I. Receptors for MCH were 
also found on rat PC12 phaeochromocytoma cells, human RE 
melanoma cells and COS-7 cells. Competition binding analyses 
with other peptides uch as ~-MSH, NPY and PACAP demon- 
strated that MCH receptor binding is specific, rANF(1-28) was 
found to be a weak competitor of MCH, indicating topological 
similarities between MCH and rANF(1-28) when interacting 
with MCH receptors. 
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I. Introduction 
The neuropeptide melanin-concentrating hormone (MCH) is 
a colour-regulating hormone in fish, binding to skin pigment 
cells to induce concentration of the intracellular pigment gran- 
ules and hence skin pallor [1]. In tetrapods, MCH is inactive 
in this respect, although high concentrations of salmonid MCH 
will induce melanin dispersion rather than concentration in 
isolated amphibian or reptile skin [2,3], and stimulate tyrosi- 
nase activity in mouse melanoma cells [3]. This effect has been 
attributed to pharmacological interaction of MCH with the 
receptors for ~-melanocyte-stimulating hormone (~-MSH) [4]. 
In higher vertebrates, MCH is abundant in the brain where its 
role is probably to serve as a widespread neurotransmitter/ 
neuromodulator [5]. Human MCH,  the structure of which is 
identical with that of rat MCH [6], is mainly located in hypotha- 
lamic neurons projecting to various other brain areas [7]. Evi- 
dence suggests that it also occurs and exerts actions in periph- 
eral organs of the body. 
Little is known about the central effects of  MCH,  and at- 
tempts to examine MCH binding sites in the brain have so far 
proved unsuccessful. A major problem has been the develop- 
ment of a satisfactory radioligand. The introduction of  an io- 
dine atom or NO2 group onto the tyrosine residue, located in 
the central region of the MCH molecule, reduced bioactivity by 
500- to 1000-fold [3,8,9], which molecular modelling suggests 
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is probably due to distortion of the shape of the cyclic structure 
[9]. N-Terminally iodinated MCH analogues, e.g. labelled with 
iodinated Bolton-Hunter eagent, bind to brain membranes 
but are rapidly degraded (unpublished observations). 
The present paper describes a very potent analogue of human 
MCH which is C-terminally iodinated and which exhibits spe- 
cific binding to mouse melanoma cells, whether or not they 
possess MSH receptors. The results indicate the existence of 
specific MCH receptors on these cells. 
2. Materials and methods 
2.1. Peptides and chemicals 
Human (rat) MCH was obtained from Bachem (Bubendorf, Switzer- 
land) or synthesized inour own laboratory. The analogue [Phe13,Tyr19] - 
MCH was prepared by the continuous-flow solid-phase method [10] 
using an automated Milligen 9050 peptide synthesizer. Cyclization of 
the linear peptide was performed by iodine oxidation followed by RP- 
HPLC purification and FAB mass spectrometic analysis of the final 
product [11]. Monoiodinated [~:5I][Phet3,Tyr~9]-MCH was obtained 
through enzymatic odination using solid-phase bound glucose oxidase/ 
lactoperoxidase, as described for ~-MSH [12], followed by a first puri- 
fication step on Spherisorb ODS minicolumns [13] and a second, pre- 
ceding each experiment, by RP-HPLC. Rat ANF(I~8), ~-MSH, pitu- 
itary adenylate cyclase activating polypeptide (PACAP) and neuropep- 
tide Y (NPY) were purchased from Bachem (Bubendorf, Switzerland). 
All chemicals and solvents were of analytical grade. 
2.2. Biossay 
The biological activity of [Phe~3,Tyr~9]-MCH was determined with 
the microscopic melanophore assay using scales from the Chinese grass 
carp, Ctenopharyngodon idellus [3]. Human (rat) MCH and salmon 
MCH served as standards. 
2.3. Cell lines and cell culture 
The following cell lines were used: mouse B16-FI melanoma, G4F 
melanoma (originating from B 16-F 1 and not expressing MSH receptors 
[14]), G4F-7 melanoma (G4F cells with transfected human MSH recep- 
tor; cells constructed inour laboratory) as well as human RE melanoma 
(isolated in our laboratory from a metastasis); rat PC12 phaeochro- 
mocytoma, COS-7, CHO (Chinese hamster ovary) and human fibro- 
blasts. The cells were grown in modified Eagle's medium (MEM) with 
Earle's salt (Gibco, Paisley, UK), supplemented with 10% heat-inac- 
tivated foetal calf serum (Amimed, Basel, Switzerland), 2 mM L-glu- 
tamine, 1% MEM non-essential mino acids (100 x ; Gibco), penicillin 
(50 units/ml) and streptomycin (50/zg/ml), using Falcon 75 and 175 cm 2 
tissue culture flasks at 37°C in a humidified atmosphere of95% air and 
5% CO2. The cells were detached with 0.02% EDTA in phosphate- 
buffered saline (8 g NaC1, 0.2 g KC1, 0.2 g KH2PO4, 1.44 g 
Na2HPO4"2H20 per liter). Cell numbers were determined in 
a haemocytometer or in a Coulter counter. 
2.4. Receptor binding assay 
The binding medium consisted of modified Eagle's medium (MEM) 
with Earle's salts (Gibco) containing 25 mM HEPES, 0.2% BSA, 0.3 
mM 1,10-phenanthroline (Merck, Darmstadt) and 0.16 mM PMSF. 
The binding reaction was started by adding 0.5 ml of a cell suspension 
(0.5-2 x 107 cells/ml) to 12 × 75 mm polypropylene tubes containing 
(i) 50/zl containing 0.05 pmol (240,000 cpm) of [~25I][Phe13,Tyrlg]-MCH 
and 50/11 of unlabelled peptide in a 1 : 3 dilution series (--*competition 
binding experiments) or (ii) 50/zl containing 0.008~0.2 pmol (40,000- 
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Fig. 1. Primary sequence of human (rat) MCH (a), [Phe~3,Tyr~9]-MCH (b), and [~25I][Phe13,Tyrlg]-MCH (c). Altered residues are underlined. 
1,000,000 cpm) of [125I][Phe13,Tyr19]-MCH and 50 HI of 0.6/,tM unla- 
belled MCH or buffer (--*saturation experiments). The cells were incu- 
bated for 90 min at 10°C. Unbound radioactivity was removed by 
centrifugation of triplicate aliquots (150/11) through a layer of 150/d 
silicon oil in 0.4 ml polyethylene microtubes [15]. The oil was made up 
to a density of 1013 kg/cm 3 by mixing equal volumes of AR-20 and 
AR-200 silicon oil (Wacker Chemie, Munich, Germany). The radioac- 
tivity was counted in an Packard Riastar ),-counter and the binding 
data were analyzed with Ligand [16], an iterative non-linear regression 
program established for Mac personal computers. 
3. Results and discussion 
The replacement of Tyr j3 by Phe and of Va119 by Tyr of the 
human (rat) MCH sequence (Fig. 1) did not alter the biological 
activity of the peptide when tested in the fish scale melanophore 
assay, the only bioassay for MCH peptides known to date: the 
analogue [Phe13,TyrI9]-MCH showed exactly the same potency 
as the parent human MCH (ECso -- 10 -~ M). This demonstrates 
that the C-terminal valine of mammalian MCH and the hy- 
droxy group of the Tyr  13 residue are not crucial for the stimu- 
lation of fish MCH receptors, which confirms similar findings 
with analogues of fish MCH [8,9]. Thus, radioiodination of 
MCH at its C-terminus appears to be much more advantageous 
than when the radiolabel is introduced at the N-terminus or 
within the ring structure. 
Binding analyses with [~25I][Phe~3,Tyr~9]-MCH and three 
mouse melanoma cell lines (B16-F1, G4F, G4F-7) and with 
human RE melanoma cells revealed that (i) all these melanoma 
cells showed specific MCH binding and (ii) binding was optimal 
between 1~15°C using a 60-90 min incubation period (Fig. 2). 
These conditions were chosen because a number of preliminary 
experiments showed that non-specific binding increases consid- 
erably at even lower temperatures, and ligand degradation and 
internalization i to the cells rises markedly at higher tempera- 
tures and after prolonged incubation (i.e. > 120 min). Highest 
specific binding was seen on the B16-F1 and G4F-7 cells. Using 
these latter cells for a detailed saturation binding analysis, a 
dissociation constant (KD) of 0.118 nmol/1 was found for the 
iodinated form of [Phe13,TyrI9]-MCH and a Bma x Of 1090 bind- 
ing sites/cell (Fig. 3). Only a single class of binding sites was 
apparent from these data. Studies with other cell lines showed 
that MCH receptors are also present on COS-7 cells and rat 
PC12 phaeochromocytoma cells, whereas they are absent on 
human skin fibroblasts and CHO cells (not shown). 
Competition binding analyses with G4F-7 cells comparing 
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Fig. 2. Time--course of specific binding of [~25I][PheJ3,Tyr~9]-MCH to 
G4F-7 cells at 10°C. The cells were incubated with 0.3 nM radioligand 
in the absence (total binding; A) or presence of 0.7 mM MCH (non- 
specific binding; o) for various time periods. Specific binding (m) was 
calculated as the difference between total and non-specific binding. 
Bound (pM) 
Fig. 3. Scatchard analysis of a typical saturation binding experiment 
using G4F-7 cells and 0.014-0.35 nM [~251][PheL3,Tyrtg]-MCH in the 
presence and absence of 60 nM MCH (main graph). In this particular 
experiment the KD was 0.1 nmol/l and Bmax was 1090 sites/cell. Total 
(A), non-specific (c 9 and specific binding (I). 
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Fig. 4. Log dose-response curve of human MCH (m) and its analogue 
[Phel3,Tyrlg]-MCH (o) in a competition binding assay with G4F-7 cells 
and [1251][PheI3,Tyr19]-MCH as radioligand. The results are the 
mean _+ S.E.M. of three independent experiments. 
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Fig. 5. Log dose-response curve of human MCH (11) and rANF(1-28) 
([]) in a competition binding assay with G4F-7 cells and 
[125I][Phe13,Tyr19]-MCH as radioligand. PACAP (*), NPY (v) and ~- 
MSH (©) were also tested as competitors. The results are the 
mean _+ S.E.M. of three independent experiments. 
human MCH with the analogue [Phe13,Tyr19]-MCH demon- 
strated that the latter is about twice as potent as the naturally 
occurring peptide (Fig. 4). Using PC12 cells, the analogue was 
still 50% more potent than human MCH (Table 1). This sug- 
gests that the binding characteristics of [Phe13,Tyr19]-MCH to 
mammalian MCH receptors hardly differ from those to fish 
MCH receptors. The different Ko values for [Phe13,Tyr19]-MCH 
obtained in saturation and competition binding experiments 
may be explained by a possibly higher affinity of the iodinated 
form of [PheI3,Tyr19]-MCH as compared to non-iodinated 
MCH peptides and/or by the fact that MCH peptides are ex- 
tremely hydrophobic, resulting in high non-specific absorption 
to plastic and tissue surfaces, which may significantly reduce 
the actual peptide concentration i  the vicinity of the receptor, 
thus lowering the amount of tracer available for receptor bind- 
ing. Nevertheless, competition binding experiments with MCH 
radioligands are useful for comparisons between different pep- 
tides and cell types. 
The specificity of MCH receptor binding was investigated 
using ~-MSH, rANF(1-28), PACAP and NPY as displacing 
peptides (Fig. 5; Table 1). The latter two peptides were included 
because PC12 cells have been reported to contain receptors for 
both PACAP [17] and NPY [18]. Neither PACAP, NPY nor 
~-MSH showed any displacement activity in the different cell 
Table 1 
Binding characteristics of different peptides to MCH receptors on 
mouse B 16-F 1, G4F and G4F-7 cells and rat PC 12 phaechromocytoma 
cells 
Peptide Dissociation constants, K o (nmol/l + S.E.M.) 
B16-F1 G4F G4F-7 PC12 
h/rMCH 14 + 5.3 120 + 12 12 + 4.5 120 + 7.8 
rANF(1-28) 180+20 n.d. 116+ 11.3 280+35.6 
ct-MSH >> 10,000 >> 10,000 >> 10,000 >> 10,000 
PACAP, NPY n.d. n.d. n.d. >> 10,000 
[Phel3,Tyrt9]-MCH n.d. n.d. 6.3 + 1.1 80.0 + 2.1 
Dissociation constants were calculated from competition binding as- 
says using t251-1abeled [Phel3,TyrJ9]-MCH; n.d., not determined. 
lines. In particular the latter finding is important because it has 
been suggested that, on melanophores, MCH will bind to MSH 
receptors [19], and conversely it could be expected that 0~-MSH 
binds to MCH receptors. This can now be ruled out for MCH 
receptors on melanoma cells. In order to answer the question 
of whether MCH may bind to MSH receptors on melanoma 
cells, we compared B16-F1 cells (expressing normal mouse 
MSH receptors) with G4F cells (lacking MSH receptors) and 
G4F-7 cells (containing human MSH receptors). MCH binding 
was observed in all three cell lines whether or not they express 
MSH receptors (Table 1). However, the binding affinity was 
about 10-fold lower in the G4F cells; a significant change in 
Bmax could not be measured (not shown). Similar results were 
obtained with PC12 cells which also lack the MSH receptor 
[20]. From these studies, it is not yet clear whether MCH recep- 
tor binding is influenced by the presence or absence of the MSH 
receptor or whether the lower affinity observed in G4F and P 12 
cells is merely an unrelated coincidence. The fact that ct-MSH 
did not displace the MCH radioligand in the different cell lines 
proves that the site for MCH-receptor binding is different from 
that for MSH. 
The cyclic peptide rANF(1 28) was a weak competitor for 
[125I][Phe13,Tyr19]-MCH when studied on mouse melanoma nd 
rat phaeochromocytoma cells. Although there is a significant 
sequence similarity between the N-terminal regions of the pro- 
hormones for the two peptides, the primary sequence of 
rANF(1-28) differs from that of [PheI3,Tyrl9]-MCH [21]. How- 
ever, it cannot be ruled out that there are topological similari- 
ties within parts of the three-dimensional structure of the two 
molecules. On the other hand, it is interesting to note that 
salmonid MCH is a very weak competitor for [125I][PheJ3,Tyr19]- 
MCH when tested with G4F-7 cells, although the two mole- 
cules share 80% sequence identity (unpublished observation). 
The physiological relevance of rANF(1-28) binding to the 
MCH receptor is not yet clear but may reside in a similar 
function of ANF  and MCH with respect o water homeostasis 
[22,23]. 
In conclusion, the preparation and application of the new 
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MCH radioligand, [125I][Phe13,Tyr19]-MCH, has made it possi- 
ble to demonstrate the existence of MCH receptors on mela- 
noma and other cell lines and to analyze some of their binding 
characteristics. These studies will form the basis for a more 
detailed analysis of MCH receptor structure and function. 
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